METTL3 mediates resistance to other chemotherapeutic drugs, including platinum‐etoposide in Small Cell Lung Cancer (SCLC), doxorubicin, 5‐fluorouracil (5‐FU), and oxaliplatin in CRC, Idarubicin in AML, and docetaxel in breast cancer.114, 118, 119, 120, 121, 122. The gene discussed is METTL3; the disease is small cell lung carcinoma.